Navigation Links
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Date:6/1/2009

WAYNE, N.J. and EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar(R) (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments.

"Nexavar has proven efficacy in liver cancer and kidney cancer and we are committed to researching Nexavar in a variety of other solid tumors," said Dimitris Voliotis, MD, vice president, Nexavar Clinical Development, Bayer HealthCare Pharmaceuticals. "Based on the results of a signal generating Phase 2 study, Bayer and Onyx initiated this Phase 3 trial to evaluate Nexavar in non-small cell lung cancer."

Phase 3 Trial Design

The MISSION (Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer) trial, is an international multicenter study that will enroll approximately 850 patients with advanced relapsed or refractory non-squamous NSCLC who have failed two or three previous treatments. Patients will be randomized to receive either Nexavar as single agent or placebo. In both treatment arms, best supportive care will be provided. The primary endpoint of this trial is overall survival, and secondary endpoints include progression-free survival and overall response rate. The safety and tolerability of the two treatment groups will also be compared.

The study will be conducted at more than 120 sites in North America, South America, Europe, Africa and the Asia-Pacific region, including Japan. For information about this study, please visit www.clinicaltrials.gov.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. IVCC launches groundbreaking insecticide projects with Bayer and Syngenta
2. AUDIO from Medialink and Bayer: Simple, Focused Ways to Boost Womens Health
3. Bayer HealthCare Cleared to Acquire Citracal(R)
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Bayer Foundation Grant Creates Graduate Engineering Fellowship at University of Houston
6. AUDIO from Medialink and Bayer: Is Your Pain Reliever Undermining Your Aspirin Therapy?
7. Bayer Temporarily Suspends Global Trasylol(R) Marketing
8. AUDIO from Medialink and Bayer: Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained with Naproxen Sodium
9. Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials
10. Bayer Awards Making Science Make Sense Grant to Girl Scouts
11. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... New York, New York (PRWEB) August 21, 2014 ... allege the blood thinner caused patients to suffer uncontrollable ... in U.S. courts, Bernstein Liebhard LLP reports. According to ... August 14th in U.S. District Court, Easter District of ... who died due to a bleeding event that was ...
(Date:8/21/2014)... 21, 2014 Lauren Collura, a mother of ... “Back to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and ... four-bedroom beachfront house in Lavallette beginning this Saturday. , ... Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue Shield of ... Superstorm Sandy and decided to make it a new summer ...
(Date:8/21/2014)... Steven Reinberg HealthDay Reporter ... of U.S. teens using sunscreen dropped nearly 12 percent in ... same time period, the number of teens using indoor tanning ... sunscreen increase the risk of skin cancers, including deadly melanomas, ... the overall percentage of teens who reported wearing sunscreen, from ...
(Date:8/21/2014)... August 21, 2014. Researchers have published a study ... of patients with motor complete spinal cord injury ... functioning at discharge and follow-up among patients with ... print on August 2 by the Archives ... Findings included small but significant differences in self-care ...
(Date:8/21/2014)... August 21, 2014 CarePoint Health ... Amish P. Patel, MD, and Sujoy Menon, MD, ... Dr. Patel and Dr. Menon to the community. ... of diagnostic imaging services to patients in Hudson ... Center, Christ Hospital and Hoboken University Medical Center. ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:Two Top Radiologists Join CarePoint Health 2
... Survey finds children and their children are ... March 27 (HealthDay News) -- Alzheimer,s care in the ... suggests. , Three in five so-called "sandwich" caregivers who ... said their children help with care duties, ranging from ...
... Unveiling a Secure, Convenient Solution to Identify Blood ... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a leader ... a proud sponsor at the spring,2008 AABB Conference ... association formerly known as the American Association of,Blood ...
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... free dental screening, DALLAS, March 27 ... Computer Services, Inc. (ACS) will,sponsor free dental education ... 28. The event will be held for pupils ... in Dallas, starting at 9:00 a.m., The ...
... study ... participants, MINNEAPOLIS, ... Minnesota Cancer Center and ClearWay Minnesota(SM) found that,since the Freedom to ... significantly reduced exposure to a,tobacco-specific cancer causing chemical., The study ...
... Up, and Changes Lives, One Smile at ... a Time via Operation Smile Partnership, CINCINNATI, March 26 ... to host an upcoming award show,Samantha Harris knows firsthand the importance ... has partnered with Oral-B Satin,Floss to not only show people how ...
Cached Medicine News:Health News:With Alzheimer's, It Takes a Family 2Health News:With Alzheimer's, It Takes a Family 3Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 2Health News:BIO-key(R) to Sponsor and Exhibit at AABB Spring Conference 3Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:ACS Expands National Dental Outreach Program to Dallas 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 2Health News:U of M Study Provides First Scientific Evidence That the Freedom to Breathe Act is Creating Healthier Workplaces for Hospitality Employees 3Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 2Health News:Samantha Harris and Oral-B Satin Floss Partner to Share Smiles 3
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... ... ... - Spasticity Affects a Significant Number of Post-Stroke ... , , ...
... Robbins & Myers, Inc. (NYSE: RBN ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of ...
Cached Medicine Technology:First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: